{"id":"W2985852779","doi":"10.1182/blood-2019-125189","title":"Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Providence Health Care; Vancouver General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Fludarabine; Chemoimmunotherapy; Alemtuzumab; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Ibrutinib; Bendamustine; Hazard ratio; Population; Proportional hazards model; Oncology; Univariate analysis; Neutropenia; Leukemia; Lymphoma; Multivariate analysis; Chemotherapy; Transplantation; Confidence interval; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004210506,0.0001755111,0.0004081831,0.000664535,0.0007952664,0.0009000393,0.0005314952,0.0003772203,0.001503126],"category_scores_gemma":[0.001372294,0.0002370325,0.0003854203,0.002759353,0.0003472918,0.0002522384,0.0006105556,0.0007932554,0.0002714544],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005601897,"about_ca_system_score_gemma":0.00469371,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5251932,"about_ca_topic_score_gemma":0.5844376,"domain_scores_codex":[0.9994961,0.00005293546,0.00006203963,0.0001034138,0.0001379309,0.000147534],"domain_scores_gemma":[0.9985158,0.0001795211,0.0005725542,0.00005601229,0.0002562477,0.0004198731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002056145,0.00002634686,0.9957067,0.00003383665,0.00005517135,0.0001471082,0.000124188,0.00009009711,0.00008542589,0.0000151178,0.0006423051,0.002868091],"study_design_scores_gemma":[0.00002794117,0.0000857563,0.9979283,0.00003972831,0.00006215428,0.0003134823,0.0003605236,0.0001871818,0.00004607339,0.00002235681,0.0009200602,0.000006396757],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946385,0.001289335,0.00005927385,0.0001362172,0.000007109068,0.00002247058,0.003108393,0.000007578288,0.0007311185],"genre_scores_gemma":[0.9963138,0.0007317279,0.00005890624,0.0001025472,0.000009529243,0.00001937947,0.002376095,0.000004776097,0.0003832242],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4748068,"threshold_uncertainty_score":0.955206,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01042038514114443,"score_gpt":0.2485973792946909,"score_spread":0.2381769941535465,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}